• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Stoke Therapeutics Inc (NQ: STOK )

    12.86 +0.50 (+4.05%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 440,464
    Open 12.40
    Bid (Size) 12.06 (5)
    Ask (Size) 13.00 (2)
    Prev. Close 12.36
    Today's Range 12.36 - 12.92
    52wk Range 3.770 - 17.58
    Shares Outstanding 44,188,534
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
    From Stoke Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +119.45%
    +119.45%
    1 Month
    +3.96%
    +3.96%
    3 Month
    -12.64%
    -12.64%
    6 Month
    +10.01%
    +10.01%
    1 Year
    +215.20%
    +215.20%

    More News

    Read More
    A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
    Via Benzinga
    Analyst Expectations For Stoke Therapeutics's Future
    Via Benzinga
    Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
    Via Benzinga
    Stoke Therapeutics to Present at Upcoming Investor Conferences in September
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
    Via Benzinga
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Present at Upcoming Investor Conferences in June
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
    From Stoke Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
    From Stoke Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    What's Going On With Stoke Therapeutics Stock Tuesday?
    Via Benzinga
    Stoke Therapeutics Announces Proposed Public Offering
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.